Addressing Key Translational Challenges of Base Editing Technology
Time: 1:45 pm
day: Day 2 Track B PM
Details:
- For somatic base editing programs, how can a drug sponsor prove no germline edits have occurred?
- Detection of on- and off-target genome editing events in the clinical setting
- Outlining the unique regulatory considerations for clearing an IND with a base editing program
